发明公开
EP0248516A1 Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations
失效
组合物和使用白介素-2和/或干扰素-β和肿瘤坏死因子的组合治疗或用于药物或制剂的制备。
- 专利标题： Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations
- 专利标题（中）： 组合物和使用白介素-2和/或干扰素-β和肿瘤坏死因子的组合治疗或用于药物或制剂的制备。
-
申请号： EP87303120.7申请日： 1987-04-09
-
公开(公告)号： EP0248516A1公开(公告)日： 1987-12-09
- 发明人: Winkelhake, Jeffrey Lee , Zimmerman, Robert
- 申请人： CETUS CORPORATION
- 申请人地址： 1400 Fifty-Third Street Emeryville California 94608 US
- 专利权人： CETUS CORPORATION
- 当前专利权人： CETUS CORPORATION
- 当前专利权人地址： 1400 Fifty-Third Street Emeryville California 94608 US
- 代理机构： Bizley, Richard Edward
- 优先权： US849713 19860409; US884548 19860711; US943608 19861218
- 主分类号： A61K37/02
- IPC分类号： A61K37/02 ; A61K37/66
摘要：
Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-β, or of TNF, IL-2 and IFN-β in combination. The composition of TNF and IL-2 and/or IFN-p may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, and lymphoma.
公开/授权文献
信息查询
